Clinical Study

A Phase 1B Study Evaluating The Safety, Tolerability And Immunogenicity Of Cmb305 (Sequentially Administered Lv305 And G305) In Patients With Locally Advanced, Relapsed, Or Metastatic Cancer Expressing Ny-Eso-1

Posted Date: Jan 20, 2016

  • Investigator: John Morris
  • Specialties: Breast Cancer, Hematology/Oncology, Oncology, Cancer, Lung Cancer
  • Type of Study: Drug

The purpose of this study is to evaluate the safety of the investigational study agent, CMB305. It is also designed to evaluate its ability to stimulate the body’s immune system against NY-ESO-1 and your tumor. “Investigational” means that the agent is being studied. It also means that the FDA (U.S. Food and Drug Administration) has not approved this agent for use in patients. This is including people with your type of cancer. In early trials of investigational agents such as CMB305, the main goal is to make sure the agent is safe. You should understand that direct clinical benefit should not be expected. What is learned from your participation will contribute important information in the development of this study agent as a possible cancer therapeutic.


To Be Eligible To Participate, Patients Must Have Been Diagnosed With Locally Advanced, Relapsed, And/Or Metastatic Cancer That Is Not Rapidly Increasing In Size And That Has Failed Standard Therapy Or Is Not Expected To Have Been Cured With Prior Therapy.


Cancer, Imdz-C131, Phase I, Relapsed Or Metastatic , Solid Tumor

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.